US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ERShares Entrepreneurs ETF

15.31

0.0000

Volume:- -

Turnover:4.92K

Market Cap:84.21M

PE:- -

High:15.31

Open:15.31

Low:15.31

Close:15.31

52wk High:16.00

52wk Low:10.72

Shares:5.50M

Float Shares:5.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:0.48

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENTR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ENTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTR\",,,,,undefined,":{"symbol":"ENTR","market":"US","secType":"STK","nameCN":"ERShares Entrepreneurs ETF","latestPrice":15.31,"timestamp":1724875200000,"preClose":15.31,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":5500000,"shares":5500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"08-28 16:00:00 EDT","open":15.31,"high":15.31,"low":15.31,"amount":4922.4664,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"symbolChange":{"newSymbol":"XOVR","executeDate":"2024-08-29"},"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":15.31,"sharesOutstanding":5500000,"nav":15.28,"aum":312010163.4,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTR\",,,,,undefined,":{"symbol":"ENTR","floatShares":5500000,"roa":"--","roe":"--","lyrEps":0,"shares":5500000,"dividePrice":0,"high":15.31,"amplitude":0,"preClose":15.31,"low":15.31,"week52Low":10.72,"pbRate":"0.48","week52High":16,"institutionHeld":0,"latestPrice":15.31,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":15.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENTR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-29","symbol":"ENTR","oldSymbol":"ENTR","defaultRemindTime":1724938200000,"newSymbol":"XOVR","exchange":"NYSE","type":"symbolChange","dateTimestamp":1724904000000},{"market":"US","date":"2021-12-21","symbol":"ENTR","amount":3.9863,"defaultRemindTime":1640097000000,"name":"熵通科技","recordDate":"2021-12-28","payableDate":"2021-12-22","currency":"USD","type":"dividend","dateTimestamp":1640062800000},{"market":"US","date":"2020-12-21","symbol":"ENTR","amount":0.911823,"defaultRemindTime":1608561000000,"name":"熵通科技","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000},{"market":"US","date":"2019-12-19","symbol":"ENTR","amount":0.014354,"name":"熵通科技","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-18","symbol":"ENTR","amount":0.000729,"name":"熵通科技","currency":"USD","type":"dividend","dateTimestamp":1545109200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENTR\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-18","recordDate":null,"paymentDate":null,"value":0.000729,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":null,"value":0.014354,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":null,"value":0.911823,"currency":"USD"},{"executeDate":"2021-12-21","recordDate":"2021-12-22","paymentDate":"2021-12-28","value":3.9863,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENTR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521759746","title":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping","url":"https://stock-news.laohu8.com/highlight/detail?id=2521759746","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521759746?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon sk","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047704/0/en/Entrada-Therapeutics-Receives-Authorization-in-the-United-Kingdom-to-Initiate-ELEVATE-45-201-a-Phase-1-2-Multiple-Ascending-Dose-Clinical-Study-of-ENTR-601-45-in-People-Living-with.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4211","TRDA","ENTR","PMO","BK4139","UBCP"],"gpt_icon":0},{"id":"2513253937","title":"Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2513253937","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513253937?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:43","pubTimestamp":1740401006,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics  said Monday that the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.The company said the 1b study is designed to evaluate ENTR-601-44's safety and tolerability in about 32 adults with DMD who are exon-44 skipping amenable.Shares of Entrada Therapeutics were up more than 9% in recent premarket activity Monday.Price: 14.28, Change: +1.24, Percent Change: +9.51","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENTR","LENZ","BK4139","TRDA"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ENTR\",params:#limit:6,delay:false,,,undefined,":[]}}